All In Biotech

Drug Trial Radar · NCT03452943

Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Feb 5, 2018

Primary completion

Nov 12, 2019

Study completion Nov 12, 2019

Sponsor

Sponsor type
Industry
Collaborators
Nuvelution TS Pharma, Inc.
First posted
Mar 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.

Conditions

  • Tourette Syndrome

Interventions

  • TEV-50717Drug

    6, 9, 12, 15, and 18 mg oral tablets

  • PlaceboDrug

    Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the TTS of the YGTSS at Week 12Time frame: Baseline, Week 12

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 046-0104

    Dothan, Alabama

  • Teva Investigational Site 046-0117

    Sun City, Arizona

  • Teva Investigational Site 046-0107

    Rogers, Arkansas

  • Teva Investigational Site 046-0126

    Anaheim, California

  • Teva Investigational Site 046-0101

    Sacramento, California

  • Teva Investigational Site 046-0111

    San Diego, California

  • Teva Investigational Site 046-0130

    Santa Ana, California

  • Teva Investigational Site 046-0132

    Miami, Florida

  • Teva Investigational Site 046-0115

    Orlando, Florida

  • Teva Investigational Site 046-0114

    St. Petersburg, Florida

  • Teva Investigational Site 046-0116

    Atlanta, Georgia

  • Teva Investigational Site 046-0133

    Naperville, Illinois

  • Teva Investigational Site 046-0128

    Boston, Massachusetts

  • Teva Investigational Site 046-0110

    Saint Charles, Missouri

  • Teva Investigational Site 046-0134

    Lincoln, Nebraska

  • Teva Investigational Site 046-0109

    Voorhees Township, New Jersey

  • Teva Investigational Site 046-0124

    New York, New York

  • Teva Investigational Site 046-0102

    Rochester, New York

  • Teva Investigational Site 046-0112

    Rochester, New York

  • Teva Investigational Site 046-0125

    Raleigh, North Carolina

  • Teva Investigational Site 046-0106

    Oklahoma City, Oklahoma

  • Teva Investigational Site 046-0113

    Dallas, Texas

  • Teva Investigational Site 046-0108

    Houston, Texas

  • Teva Investigational Site 046-0103

    Houston, Texas

  • Teva Investigational Site 046-0120

    San Antonio, Texas

  • Teva Investigational Site 046-0105

    Orem, Utah

  • Teva Investigational Site 046-0118

    Petersburg, Virginia

  • Teva Investigational Site 046-0201

    Ajax, Ontario, Canada

  • Teva Investigational Site 046-0202

    Ottawa, Ontario, Canada

  • Teva Investigational Site 046-0302

    Herlev, Denmark

  • Teva Investigational Site 046-0301

    Odense, Denmark

  • Teva Investigational Site 046-0702

    Stavropol, Russia

  • Teva Investigational Site 046-0704

    Tomsk, Russia

  • Teva Investigational Site 046-0703

    Voronezh, Russia

  • Teva Investigational Site 046-1702

    Belgrade, Serbia

  • Teva Investigational Site 046-1703

    Belgrade, Serbia

  • Teva Investigational Site 046-1701

    Novi Sad, Serbia

  • Teva Investigational Site 046-0604

    Barcelona, Spain

  • Teva Investigational Site 046-0605

    Madrid, Spain

  • Teva Investigational Site 046-0602

    Madrid, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.